Microtubules as a target for anticancer drugs

@article{Jordan2004MicrotubulesAA,
  title={Microtubules as a target for anticancer drugs},
  author={Mary Ann Jordan and Leslie Wilson},
  journal={Nature Reviews Cancer},
  year={2004},
  volume={4},
  pages={253-265}
}
Highly dynamic mitotic-spindle microtubules are among the most successful targets for anticancer therapy. Microtubule-targeted drugs, including paclitaxel and Vinca alkaloids, were previously considered to work primarily by increasing or decreasing the cellular microtubule mass. Although these effects might have a role in their chemotherapeutic actions, we now know that at lower concentrations, microtubule-targeted drugs can suppress microtubule dynamics without changing microtubule mass; this… 
Microtubule Targeting Anti-mitotic Agents as Anti-Cancer Drugs: A Review
TLDR
Among the most successful microtubule-targeted chemotherapeutic drugs are paclitaxel and the Vinca alkaloids, which act through the suppression of micro Tubulin dynamics, rather than increasing or decreasing microtubules-polymer mass.
New Microtubule / Tubulin-Targeted Anticancer Drugs and Novel Chemotherapeutic Strategies
TLDR
A potential valuable strategy would be to use core microtubules-targeted drugs along with novel targeted drug therapies as they are developed, where the antitumor activity of a targeted drug can be combined with the power of low dose microtubule- targeted therapy.
Microtubule-binding agents: a dynamic field of cancer therapeutics
TLDR
The screening of a range of botanical species and marine organisms has yielded promising new antitubulin agents with novel properties, and the three main objectives are enhanced tumour specificity, reduced neurotoxicity and insensitivity to chemoresistance mechanisms.
Microtubule Targeting Agents
TLDR
This chapter provides an overview of microtubules physiology and the novel microtubule-targeting chemotherapeutic agents that are currently being evaluated for the treatment of taxane-refractory, castration-resistant prostate cancer.
Microtubules: A dynamic target in cancer therapy
TLDR
This review provides an overview of the mechanisms mediating resistance to tubulin‐binding agents related to the cellular target and discusses strategies to overcome this important clinical problem.
How do microtubule-targeted drugs work? An overview.
TLDR
It has been argued that microtubules represent the single best cancer target identified to date, and it seems likely that drugs in this class will continue to remain an important chemotherapeutic class of drugs even as more selective chemotherAPEutic approaches are developed.
Exploring the mechanisms of action of the novel microtubule inhibitor vinflunine.
TLDR
Key features of vinflunine are highlighted, a bifluorinated vinca alkaloid endowed with unique antitumor properties that lead to effective suppression of microtubule dynamics and induction of cell death in cancer cells.
Microtubule Targeting Agents in Cancer Therapy: Elucidating the Underlying Molecular Mechanisms
TLDR
It is crucial to understand the basic biology of microtubules and the molecular mechanisms by which MTAs exert their activity, especially important considering their current application in cancer therapy.
Microtubule assembly dynamics: An attractive target for anticancer drugs
TLDR
Benomyl, griseofulvin, and sulfonamides have been used as antifungal and antibacterial drugs and are considered to have limited toxicities; it is suggested that these drugs may have a significant use in cancer chemotherapy when used in combination with other anticancer drugs.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 191 REFERENCES
Mechanism of action of antitumor drugs that interact with microtubules and tubulin.
  • M. Jordan
  • Biology
    Current medicinal chemistry. Anti-cancer agents
  • 2002
TLDR
It can be argued that microtubules represent the single best cancer target identified to date, as considerable evidence indicates that, at lower concentrations, these drugs have a common mechanism of action; they suppress the dynamics of micro Tubulin without appreciably changing the mass of microtubule in the cell.
Microtubules and actin filaments: dynamic targets for cancer chemotherapy.
Differential mitotic responses to microtubule-stabilizing and -destabilizing drugs.
TLDR
The results suggest that the mechanism underlying aberrant mitosis may not be the same as that responsible for mitotic block, and that the former determines the sensitivity of cells to Taxol-like drugs.
Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death.
  • C. Dumontet, B. Sikic
  • Biology, Chemistry
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1999
TLDR
Data suggest that vinca alkaloids and taxanes may act synergistically as antitumor agents and may be administered as combination chemotherapy in the clinic, however, enhanced myeloid and neurologic toxicity, as well as a strong dependence on the sequence of administration, presently exclude these combinations outside the context of clinical trials.
Tubulin/microtubules: still a promising target for new chemotherapeutic agents.
TLDR
It is suggested that indanocine, a synthetic antimitotic indanone, possesses all of the properties of a chemotherapeutic agent and should be excited about “yet another” tubulin agent.
Modulation of microtubule dynamics by drugs: a paradigm for the actions of cellular regulators.
TLDR
It is clear that molecules that regulate dynamics such as Kin 1 and stathmin could bind to a large number of distinct tubulin sites on microtubules and employ an array of mechanisms to selectively and powerfully regulate microtubule dynamics and dynamics-dependent cellular functions.
Stabilization of microtubule dynamics by estramustine by binding to a novel site in tubulin: a possible mechanistic basis for its antitumor action.
TLDR
The results may explain the mechanistic basis for the benefit derived from combined use of estramustine with vinblastine or taxol, two other drugs that target microtubules, in the treatment of hormone-refractory prostate cancer.
Anticancer therapy with novel tubulin-interacting drugs.
TLDR
A number of promising 'new generation' antimitotic drugs that target the tubulin/microtubule system and display efficacy against drug-refractory carcinomas are reviewed here in terms of their mechanism(s) of action on microtubules, effectiveness againstdrug-resistant tumour cells and clinical potential.
Microtubule dynamics: taking aim at a moving target.
Mechanisms of Taxol resistance related to microtubules
TLDR
This review focuses on mechanisms of Taxol resistance that occur directly at the microtubule, such as mutations, tubulin isotype selection and post-translational modifications, and also at the level of regulatory proteins.
...
1
2
3
4
5
...